Aligos Therapeutics
South San Francisco, CA
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
aligos.comCompany Details
Founded
- 2018
Employees
- 70 employees
Raised
- $505,600,000
Headquarters Location
- South San Francisco, CA
Public
- Yes
Acquired
- No
CEO
Lawrence M. Blatt
Founders
- Lucinda QuanLeonid BeigelmanLawrence M. Blatt
Company Collections
These are collections Aligos Therapeutics is a part of. Click on the collection name to view similar companies.
Aligos Therapeutics' Industries
Aligos Therapeutics Headquarters Location
Total Amount Raised: $505,600,000
Aligos Therapeutics Funding Rounds
Post Ipo Equity
$105,000,000
Post Ipo Equity
$92,000,000
Post Ipo Equity Investors
Roche Venture FundLawrence M. BlattArmistice CapitalEcoR1 CapitalDeep Track CapitalPost Ipo Equity
$83,600,000
Series B
$125,000,000
Series B Investors
Wellington ManagementCormorant Asset ManagementBoxer CapitalJanus CapitalPivotal bioVenture PartnersLogos CapitalVersant VenturesRoche Venture FundNovo HoldingsVivo CapitalIPO
Unknown
Series A
$100,000,000
Series A Investors
Versant VenturesNovo HoldingsRoche Venture FundVivo Capital
Aligos Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Aligos Therapeutics.